Patient-reported Outcome Claims On Kepivance Site Gets Full Throated FDA Response
This article was originally published in The Pink Sheet Daily
SOBi’s oral mucositis treatment was studied in controlled trials that used patient-reported outcome measures, but their content validity has not been established, FDA’s Office of Prescription Drug Promotion says.
You may also be interested in...
Mylan direct-to-consumer ad misleadingly suggested that as long as allergy sufferers have the product with them, they don’t need to do anything else to avoid anaphylactic shock, FDA says.
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.